Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 49Brain Neoplasms 25Central Nervous System Neoplasms 22Astrocytoma 17Glioma 15Medulloblastoma 11Neoplasms 8Oligodendroglioma 7Recurrence 6Gliosarcoma 6Spinal Cord Neoplasms 2Ependymoma 2Sarcoma 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Newly Diagnosed High Grade Glioma 1Neuroectodermal Tumors, Primitive 1Neuroectodermal Tumors 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Familial ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Diffuse Intrinsic Pontine Glioma 1

Interventions

Temozolomide 1Nivolumab 1Lomustine 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Newly Diagnosed High Grade Glioma × Lomustine × CNS × Clear all
NCT03425292 2023-11-08

A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer

Saint John's Cancer Institute

Phase 1 Completed
49 enrolled
CNS

Newly Diagnosed High Grade Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡